Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 December 2022.
During the last quarter, Patrys has made significant progress in the development of its deoxymab platform – both for its own clinical program, as well in response to potential commercial partnership opportunities.
Key activities include:
- Final GLP toxicology studies of PAT-DX1 are underway and on track for completion in Q2 CY2023;
- New preclinical data announced demonstrating ability of PAT-DX3 to cross blood brain barrier in healthy animals;
- Experiments are currently underway to evaluate the use of deoxymabs for synthetic lethal approaches and the delivery of gene-editing constructs;
- Cash and short term investment balance of $5.8 million on 31 December 2022, with a $3.3 million research & development incentive refund received on 30 January 2023 (ie. a subsequent event), resulting in a pro-forma balance of $9.15 million.